Table 2
Results of conditional logistic regression analysis (CLR)
|
SNHL group (n = 15)2-150 n (%) |
Comparison group (n = 30)2-150 n (%) |
Matched sets2-151 |
Odds ratio (CLR) (95% CI) |
|
| Bilirubin > 200 + acidosis | 4/13 (30.8) | 1/29 (3.5) | 13 | 8.0 (0.9–71.6) |
| Bilirubin > 200 + sepsis | 2/14 (14.3) | 3/29 (10.3) | 14 | 1.2 (0.2–7.0) |
| Bilirubin > 200 + netilmicin | 10/14 (71.4) | 5/29 (17.2) | 14 | 14.2 (1.8–114) |
| Bilirubin > 200 + vancomycin | 1/14 (6.7) | 0 (0) | 2-152 | |
| Bilirubin > 200 + frusemide | 4/14 (26.7) | 3 (10) | 14 | 3.3 (0.6–18.9) |
| Peak bilirubin + acidosis | 2/14 (14.3) | 1/28 (3.6) | 14 | 2.6 (0.2–29.1) |
| Peak bilirubin + sepsis | 4/14 (28.6) | 2/28 (7.1) | 14 | 3.6 (0.7–19.9) |
| Peak bilirubin + netilmicin | 13 (86.6) | 4/28 (14.3) | 2-152 | |
| Peak bilirubin + frusemide | 5 (33.3) | 3/29 (10.3) | 14 | 4.3 (0.8–22.8) |
| Creatinine > 60 + netilmicin | 11/14 (78.6) | 21 (70) | 14 | 1.5 (0.3–7.5) |
| Creatinine > 60 + vancomycin | 3/14 (21.4) | 3 (10) | 14 | 3.4 (0.3–35.8) |
| Creatinine > 60 + frusemide | 9/14 (64.3) | 8 (26.7) | 14 | 8.9 (1.1–74.5) |
| Netilmicin + frusemide | 10 (66.6) | 11 (36.7) | 15 | 5.0 (0.99–24.8) |
| Vancomycin2-153 + frusemide | 4 (26.6) | 4 (13.3) | 15 | 2.7 (0.5–15.9) |
-
Data in bold are significant (p < 0.05). Creatinine (mmol/l) = bilirubin (μmol/l).
-
↵2-150 Unless otherwise stated.
-
↵2-151 Number of sets used for CLR analysis.
-
↵2-152 Convergence not possible.
-
↵2-153 No patients in the SNHL group or the comparison group were administered vancomycin at the time of peak bilirubin levels.
-
SNHL, sensorineural hearing loss.
